Related references
Note: Only part of the references are listed.Safety and efficacy of upfront plerixafor plus G-CSF versus placebo plus G-CSF for mobilization of CD34+ hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma
Ivana N. Micallef et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
An Infernal Trio: The chemokine CXCL12 and its receptors CXCR4 and CXCR7 in tumor biology
Kirsten Hattermann et al.
ANNALS OF ANATOMY-ANATOMISCHER ANZEIGER (2013)
Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma
Isabel Ben-Batalla et al.
BLOOD (2013)
Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target
Il-Kyoo Park et al.
BLOOD (2013)
Inhibitors of the TAM subfamily of tyrosine kinases: Synthesis and biological evaluation
Rosa M. Suarez et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)
Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502
Eyal C. Attar et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia
A. B. Lee-Sherick et al.
ONCOGENE (2013)
Overexpression of amyloid precursor protein in acute myeloid leukemia enhances extramedullary infiltration by MMP-2
Ling Jiang et al.
TUMOR BIOLOGY (2013)
Meta-Analysis of Microarray Data Identifies GAS6 Expression as an Independent Predictor of Poor Survival in Ovarian Cancer
Michelle Buehler et al.
BIOMED RESEARCH INTERNATIONAL (2013)
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
Geoffrey L. Uy et al.
BLOOD (2012)
Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands
Thomas Schmidt et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2012)
Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures
Jason H. Mendler et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
Klaus H. Metzeler et al.
BLOOD (2011)
TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Klaus H. Metzeler et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Targeting Axl and Mer Kinases in Cancer
Anupam Verma et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720
M. R. Baer et al.
LEUKEMIA (2011)
SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia
Ion Cristobal et al.
BLOOD (2010)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808
Jonathan E. Kolitz et al.
BLOOD (2010)
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Sebastian Schwind et al.
BLOOD (2010)
AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer
Erinn B. Rankin et al.
CANCER RESEARCH (2010)
Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study
Heiko Becker et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies
X. Ye et al.
ONCOGENE (2010)
Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3
Kristina Masson et al.
CELLULAR SIGNALLING (2009)
Prognostic Importance of MN1 Transcript Levels, and Biologic Insights From MN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Christian Langer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Clinical implications of c-Kit mutations in acute myelogenous leukemia
Muriel Malaise et al.
Current Hematologic Malignancy Reports (2009)
Axl and growth arrest - Specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme
Markus Hutterer et al.
CLINICAL CANCER RESEARCH (2008)
KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: Two novel mutations and selective occurrence in leukemia subtypes and age groups
Narongrit Sritana et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2008)
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720
Maria R. Baer et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications
Susan P. Whitman et al.
BLOOD (2008)
TAM receptors are pleiotropic inhibitors of the innate immune response
Carla V. Rothlin et al.
CELL (2007)
Novel definition files for human GeneChips based on GeneAnnot
Francesco Ferrari et al.
BMC BIOINFORMATICS (2007)
High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia:: A Cancer and Leukemia Group B study
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old
G. Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication:: a Cancer and Leukemia Group B study
Susan P. Whitman et al.
BLOOD (2007)
Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype
Sergej Konoplev et al.
CANCER (2007)
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21):: A Cancer and Leukemia Group B study
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases
Sassan Hafizi et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2006)
Molecular regulation of receptor tyrosine kinases in hematopoietic malignancies
Pamela H. Correll et al.
GENE (2006)
Genetics of myeloid malignancies:: Pathogenetic and clinical implications
S Fröhling et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22)
T Nanri et al.
LEUKEMIA (2005)
Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML
R Zheng et al.
LEUKEMIA RESEARCH (2004)
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
RA Irizarry et al.
BIOSTATISTICS (2003)
Share Paper
